Barriers and challenges for the fast treatment of bleeds in the non‐haemophilia treatment centre hospital setting
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.13956
Abstract: Early treatment for acute bleeds in patients with haemophilia and inhibitors is feasible when patients are managed in haemophilia treatment centres (HTCs). Patients may need to attend non‐HTCs for out‐of‐hours emergency care, especially if HTCs… read more here.
Keywords: treatment; haemophilia treatment; barriers challenges; challenges fast ... See more keywords
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis and haemostasis"
DOI: 10.1160/th16-06-0444
Abstract: Turoctocog alfa pegol (N8-GP) is a novel glycoPEGylated extended half-life recombinant factor VIII (FVIII) product developed for prophylaxis and treatment of bleeds in patients with haemophilia A, to enable higher activity levels with less frequent… read more here.
Keywords: treatment; safety; fviii; efficacy ... See more keywords